Voyager Therapeutics (NASDAQ:VYGR) COO Robin Swartz Sells 6,458 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,458 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $3.77, for a total value of $24,346.66. Following the sale, the chief operating officer owned 199,738 shares in the company, valued at $753,012.26. The trade was a 3.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Robin Swartz also recently made the following trade(s):

• On Tuesday, February 10th, Robin Swartz sold 4,569 shares of Voyager Therapeutics stock. The shares were sold at an average price of $3.85, for a total transaction of $17,590.65.

Voyager Therapeutics Stock Performance

VYGR stock traded up $0.03 during trading on Friday, reaching $4.26. The company had a trading volume of 26,299 shares, compared to its average volume of 581,896. Voyager Therapeutics, Inc. has a twelve month low of $2.64 and a twelve month high of $5.55. The firm has a 50-day simple moving average of $3.86 and a 200-day simple moving average of $4.11. The company has a market cap of $236.58 million, a price-to-earnings ratio of -1.97 and a beta of 1.30.

Wall Street Analyst Weigh In

VYGR has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, November 11th. Wall Street Zen cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Finally, HC Wainwright reduced their price target on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.75.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in Voyager Therapeutics in the 2nd quarter valued at $36,000. Wexford Capital LP acquired a new stake in Voyager Therapeutics during the 3rd quarter worth $42,000. ProShare Advisors LLC purchased a new stake in shares of Voyager Therapeutics during the fourth quarter worth $44,000. CIBC Asset Management Inc acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $45,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Voyager Therapeutics in the second quarter worth about $50,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.